Synchronizing obesity management with survodutide

Abstract

The therapeutic landscape for obesity is changing rapidly, driven by the recognition of obesity as a chronic, biologically heterogeneous disease, with clinically relevant organ consequences. In this context, the phase 3 SYNCHRONIZE™-1 trial of survodutide, a once-weekly dual agonist of glucagon receptor and glucagon-like peptide 1 (GLP-1) receptor, is notable not simply because it adds another effective incretin-based therapy, but because it tests a broader metabolic concept. By pairing GLP-1-mediated appetite suppression with glucagon-mediated effects on energy expenditure and hepatic lipid handling, survodutide aims to extend treatment beyond appetite control towards coordinated modulation of adiposity, cardiometabolic risk and steatotic liver disease. In adults with obesity without diabetes, SYNCHRONIZE™-1 showed sustained body-weight reductions of approximately 12–13% over 76 weeks, compared with 5.4% with placebo, and increased the proportion of participants achieving clinically ambitious weight-loss thresholds, including at least 20% weight loss. Improvements in waist circumference, glycemic and lipid measures, together with reductions in visceral and liver fat content (LFC) in imaging analyses, support the possibility of benefits that are metabolically broader than scale weight alone. Yet the trial also illustrates familiar tensions in obesity pharmacotherapy: gastrointestinal tolerability, treatment discontinuation, the absence of an active comparator, unexpectedly high placebo-associated weight loss and limited outcome data. Thus, SYNCHRONIZE™-1 should be read as an important proof of principle for dual glucagon-GLP-1 receptor agonism rather than as a definitive positioning of the therapy within the treatment landscape. The next challenge is to determine whether this mechanism delivers durable cardiovascular, renal, and hepatic benefits, and in which patient populations.

Keywords

commentary / obesity / survodutide / metabolic dysfunction-associated steatotic liver disease (MASLD) / dual incretin agonist

References

[1] Prospective Studies Collaboration; Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al. Body—mass index and cause—specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009; 373: 1083-96.

[2] Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025; 13: 221-62.

[3] Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019; 15: 288-98.

[4] Tsoi MF, Li HL, Feng Q, Cheung CL, Cheung TT, Cheung BMY. Prevalence of Childhood Obesity in the United States in 1999—2018: A 20—Year Analysis. Obes Facts. 2022; 15: 560-9.

[5] Xiao T, Yang L, Fan C, Dou Y, Shang J. Prevalence and comorbidity burden of clinical obesity in US adults. BMC Public Health. 2026; 26: e26.

[6] Lonardo A, Weiskirchen R. Liver and obesity: a narrative review. Explor Med. 2025; 6: 1001334.

[7] le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, et al. ; SYNCHRONIZE—1 Investigators. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026.

[8] Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell—Scherer D, et al. Obesity in adults: a clinical practice guideline. Can Med Assoc J. 2020; 192: E875-91.

[9] Elmaleh—Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity Management in Adults. JAMA. 2023; 330: 2000-15.

[10] Tchang BG, Aras M, Kumar RB, Aronne LJ. Endotext [Internet]. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, et al., editors. Pharmacologic Treatment of Overweight and Obesity in Adults. South Dartmouth (MA): MDText.com, Inc.; 2000.

[11] Weiskirchen R, Lonardo A. How ‘miracle’ weight—loss semaglutide promises to change medicine but can we afford the expense? Br J Pharmacol. 2025; 182: 1651-70.

[12] Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for Metabolic Dysfunction—Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024; 391: 299-310.

[13] Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025; 393: 26-36.

[14] Pirola CJ, Sookoian S. Semaglutide in MASH with F2—F3 fibrosis: a holistic perspective on the ESSENCE phase 3 trial. Metab Target Organ Damage. 2026; 6: e6.

[15] Asokkumar R. Recent advances in bariatric endoscopy for obesity management: expanding the therapeutic spectrum. Singap Med J. 2025; 66: 416—9.

[16] Campbell C, Peddi P, Rogers A, DuCoin C, Sujka J, Docimo S Jr. Comprehensive Obesity Medicine Management in Metabolic and Bariatric Surgery (COMMMBS) Algorithm: An Evidenced Based Proposal. Obes Surg. 2025; 36: 546-54.

[17] le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP—1 receptor dual agonist survodutide for obesity: a randomised, double—blind, placebo—controlled, dose—finding phase 2 trial. Lancet Diabetes Endocrinol. 2024; 12: 162-73.

[18] Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. Dose—response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP—1 receptor agonist, compared with placebo and open—label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2023; 67: 470-82.

[19] Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024; 391: 311—9.

[20] Zimmermann T, Thomas L, Baader—Pagler T, Haebel P, Simon E, Reindl W, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP—1R dual agonist with robust anti—obesity efficacy. Mol Metab. 2022; 66: 101633.

[21] Thomsen J, Kristiansen K, Brunfeldt K, Sundby F. The amino acid sequence of human glucagon. FEBS Lett. 1972; 21: 315—9.

[22] Gasbjerg LS, Nielsen CK, Suppli MP, Grøndahl MFG, Holst JJ, Knop FK, et al. Proglucagon—derived peptides: human physiology and therapeutic potential. Physiol Rev. 2026; 106: 529-86.

[23] Krueger J, Dieskau AP, Hassfeld J, Gries J, Block O, Weinmann H, et al. Chemical Process Development in the Pharmaceutical Industry in Europe—Insights and Perspectives from Industry Scientists. Angew Chem Int Ed. 2025; 64: e202420719.

[24] le Roux CW, Wharton S, Bozkurt B, Platz E, Bleckert G, Ajaz Hussain S, et al. Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double—blind, placebo—controlled, phase 3 trial (SYNCHRONIZE™—1). Diabetes Obes Metab. 2025; 28: 337-46.

[25] Kaplan LM, Startseva E, le Roux CW, Wharton S, Bozkurt B, Mazo DF, et al. Survodutide in adults with obesity and metabolic dysfunction—associated steatotic liver disease: SYNCHRONIZE—MASLD, a randomized, double—blind, placebo—controlled phase 3 trial. Nat Med. 2026; 32: 2948-58.

[26] Yokote K, Yamauchi T, Fukushima Y, Takatsuka Y, Kato M, Yan S, et al. Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE—JP Trial. Diabetes Obes Metab. 2026; 28: 6595-606.

[27] Karagiannis T, Malandris K, Avgerinos I, Stamati A, Kakotrichi P, Liakos A, et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta—analysis of randomised controlled trials. Diabetologia. 2024; 67: 1206-22.

[28] Zimmermann T, Bleymehl K, Haebel P, Perens J, Roostalu U, Hecksher—Sørensen J, et al. Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation. Mol Metab. 2026; 105: 102326.

[29] Kosiborod MN, Platz E, Wharton S, le Roux CW, Brueckmann M, Ajaz Hussain S, et al. Survodutide for the Treatment of Obesity. JACC: Heart Fail. 2024; 12: 2101—9.